Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

In a report released on September 20, Marie Thibault from BTIG maintained a Buy rating on Masimo (MASI – Research Report), with a price ...

Commercial partner Ascensia is in discussions with insulin pump manufacturers to create an automated insulin delivery system.

Senseonics Holdings Inc (SENS) stock saw a decline, ending the day at $0.41 which represents a decrease of $-0.03 or -6.82% from the prior close of $0.44. The stock opened at $0.49 and touched a low ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...

Senseonics Holdings Inc (SENS) stock saw a decline, ending the day at $0.39 which represents a decrease of $-0.02 or -4.88% from the prior close of $0.41. The stock opened at $0.41 and touched a low ...

Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...

Senseonics Holdings, Inc. (NYSE: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with ...